摘要
目的评价18岁以上人群接种四价流感病毒灭活疫苗（QIV）免疫原性和安全性。方法检索美国国家医学图书馆数据库、Cochrane协作网图书馆、中国生物医学文献数据库、中国期刊全文数据库和万方全文数据库，将有关比较18岁以上人群接种QIV和三价流感病毒灭活疫苗（TIV）免疫原性和安全性的随机对照试验纳入分析。以接种疫苗21d后产生的针对H1N1、H3N2、B／Victoria、B／Yamagata四个疫苗株的抗体保护率（SPR）和抗体阳转率（SCR）以及不良反应发生率作为结局指标，合并组间的SPR、SCR和不良反应发生率的相对危险度（RR）。结果共纳入5篇文献。针对B／Yamagata的SPR的RR是1．12（95％CI：1．02～1．22），SCR的RR是2．11（95％CI：1．51～2．95）。针对B／Victoria的SPR的RR是1．14（95％CI：1．03-1．25），SCR的RR是1．78（95％CI：1．24—2．55）。接种QIV和，TIV（含B／Yamagata）后接种部位疼痛发生率的RR是1．23（95％CI：1．05—1．44）。结论18岁以上成人接种QIV不仅可以产生与TIV相似的免疫效果和安全性，而且可以对TIV未包含的乙型流感疫苗株产生较好免疫效果。
Objective To evaluate the immunogenicity and safety of inactivated quadrivalent influenza vaccine （QIV） in adults aged above 18 years. Methods The random control trials （RCT） in adults aged above 18 years for comparing and analyzing the immunogenicity and safety between QIV and trivalent influenza vaccine （TIV） were searched in major online databases including National Center for Biotechnology Information （NCBI） , Cochrane Library （CL）, China Biology Medicine disc （CBMd）, China National Knowledge Infrastructure （CNKI） and Wanfang Database. Sero-protection rate （SPR）, sero-conversion rate （SCR） against H1N1, H3N2, B/ Victoria, B/Yamagata and incidence rate of adverse events with an interval of 21 days after vaccination were considered as endpoints and relative risk （RR） of SPR, SCR and incidence rate of adverse effect was combined. Results A total of 5 studies were enrolled. The meta-analysis result showed that pooled RRs for SPR and SCR of B/Yamagata were 1.12（95%CI： 1.02-1.22） and 2.11 （95%CI： 1.51-2.95）, respectively; while pooled RRs for SPR and SCR of B/Victoria were 1.14 （95%CI： 1.03-1.25） and 1.78 （95%CI： 1.24-2.55）, respectively. Compared to TIV with B/Yamagata, injection site pain was more common for QIV, with a pooled RR of 1.23 （95%CI： 1.05- 1.44）. Conclusions In adults aged above 18 years, QIV has the similar immunogenic effect and safety with TIV, and a superior immunogenic effect to the vaccine strain that is not included in TIV.
作者
胡昱
李倩
陈雅萍
汪颖
沈灵智
Hu Yu Li Qian Chen Yaping Wang Ying Shen Lingzhi(Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou 310051, China)
出处
《国际流行病学传染病学杂志》
CAS
2017年第1期47-52,共6页
International Journal of Epidemiology and Infectious Disease
作者简介
通信作者：胡昱，Email：husix@163．com
